Why I Wouldn't Touch Novavax With a 10-Foot Pole [Yahoo! Finance]
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: Yahoo! Finance
10 stocks we like better than Novavax › Novavax (NASDAQ: NVAX) was once a leading contender to dominate the coronavirus vaccine market. The company faced several challenges, however, and although it successfully launched its vaccine, Nuvaxovid, revenue and earnings have remained inconsistent for years, and the stock has delivered subpar returns. Unfortunately for Novavax, it is unlikely to perform significantly better over the medium term. Here's why it'd be best for investors to avoid this company. Last year, Novavax signed an agreement with Sanofi, granting the France-based biotech giant the rights to commercialize Nuvaxovid in the U.S. and other countries worldwide. Sanofi also acquired the right to use Novavax's proprietary Matrix-M adjuvant technology in some of its vaccines in development. The deal was worth an upfront payment of $500 million and up to $700 million in payments upon hitting certain milestones, in addition to royalties on sales of Nuvaxovid and other produc
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- Novavax (NASDAQ:NVAX) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Novavax, Inc. (NVAX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Pharma Stocks Fall After Leaked Memo Questions Vaccine Safety [Barron's]Barrons
- Vaccine makers fall on FDA memo, Bally's wins bid for NYC casino [Yahoo! Finance Canada]Yahoo! Finance Canada
- Moderna Falls as FDA Vows to Impose New Vaccine Requirements [Yahoo! Finance Canada]Yahoo! Finance Canada
NVAX
Earnings
- 11/6/25 - Miss
NVAX
Sec Filings
- 11/12/25 - Form SCHEDULE
- 11/6/25 - Form 8-K
- 11/6/25 - Form 10-Q
- NVAX's page on the SEC website